# NeuroPace share price today (NeuroPace, Inc., NPCE)

> NeuroPace, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. NPCE · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/npce

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $12.31 (+23.8% in a year)
- Revenue (Jun 2026): $22.8 M
- Profit (Jun 2026): −$6.2 M
- Operating margin: −22.5%
- ROE: −113%, FY25
- ROIC: −8.8%, against a 13.8% cost of capital: −22.6 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the NeuroPace share price today? NeuroPace, Inc.'s share price was $12.31 at the close on 3 November 2026. That is 17.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $12 and $18, and at that close it sat 1% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 17 weeks running. Over the last 1 year the share price moved +29% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 10 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does NeuroPace pay? NeuroPace, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is NeuroPace on? NeuroPace is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is NeuroPace profitable? NeuroPace, Inc. posted a net loss of $6.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $21.5 M. That loss is 27.2% of the quarter's revenue. The same quarter a year earlier lost $7.5 M. 8 of the last 8 reported quarters were loss-making. ## How much revenue does NeuroPace make, and is it growing? NeuroPace, Inc. reported $22.8 M of revenue in the Jun 2026 quarter. Over 4 years it has grown 22.0% a year on average. The last full year, FY25, came in at $100.0 M. The quarterly figures for FY25 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $100.0 M, +25.1% on the year before. ## How much of every $100 of sales does NeuroPace keep? NeuroPace, Inc.'s operating margin was −22.5% in the Jun 2026 quarter. Across 5 years it has been between −89.6% and −16.3%. The latest quarter is within that range. Why the margin moved: operating margin changed +9.9 percentage points on the year while gross margin changed +9.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is NeuroPace's profit turning into cash? NeuroPace, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $11.0 M of cash, against −$21.5 M of profit. After $332 K of spending on assets, free cash was −$11.3 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does NeuroPace's cash go? NeuroPace, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $811 K on assets over the last 3 years. Averaged over those years that is 0.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $811 K over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is NeuroPace's P/E ratio, and how does it compare with its own history? NeuroPace, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values NeuroPace, Inc. at 4.2× its FY25 revenue of $100.0 M. The P/E comes back here once profit turns positive. ## Is the NeuroPace business getting better or worse? NeuroPace, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does NeuroPace earn on its capital? NeuroPace, Inc. earned a ROE of −113% in FY25. That is up from a low of −339% in FY24. Its return on capital used (ROIC) is 22.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −21.5% net margin and 0.95× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −21.5% net margin × 0.95× asset turnover × 5.55× leverage (assets divided by equity) ≈ −113.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −8.8% − 13.8% = −22.6 percentage points. The 13.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does NeuroPace have too much debt? NeuroPace, Inc. has total debt of $69.9 M against shareholder equity of $11.9 M as of Jun 2026, so its debt is 5.88× its equity. Year by year, that ratio went from 0.68 in FY21 to 3.72 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the NeuroPace shareholding pattern? 3.5% of NeuroPace, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 7.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is NeuroPace from balance-sheet trouble? For NeuroPace, Inc., the Z-score is −3.45. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −3.45 is inside the danger zone, so the balance sheet is a real risk. ## How does NeuroPace rank in its industry? There is no score against its industry: NeuroPace, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is NeuroPace compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to NeuroPace in size? NeuroPace is the 60th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: SS Innovations International, Inc., BrainsWay and 908 Devices Inc. Just below it: Viemed Healthcare, Inc., Orthofix Medical Inc. and CapsoVision, Inc. ### Medical Devices companies close in size

1. [SS Innovations International, Inc.](https://www.sectoralpha.in/us/stocks/ssii) $467 million
2. [BrainsWay Ltd.](https://www.sectoralpha.in/us/stocks/bway) $448 million
3. [908 Devices Inc.](https://www.sectoralpha.in/us/stocks/mass) $441 million
4. NeuroPace, Inc. $423 million
5. [Viemed Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/vmd) $360 million
6. [Orthofix Medical Inc.](https://www.sectoralpha.in/us/stocks/ofix) $357 million
7. [CapsoVision, Inc.](https://www.sectoralpha.in/us/stocks/cv) $335 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Magnera Corporation](https://www.sectoralpha.in/us/stocks/magn) $422 million · Household & Personal Products
2. [Oxford Industries, Inc.](https://www.sectoralpha.in/us/stocks/oxm) $422 million · Apparel Manufacturing
3. NeuroPace, Inc. $422 million
4. [YD Bio Limited](https://www.sectoralpha.in/us/stocks/ydes) $421 million · Biotechnology
5. [Aspen Aerogels, Inc.](https://www.sectoralpha.in/us/stocks/aspn) $419 million · Building Products & Equipment

## What else do people ask about NeuroPace? ### What were NeuroPace's latest quarterly results? NeuroPace, Inc. reported revenue of $22.8 M and a net loss of $6.2 M for the Jun 2026 quarter. Earnings per share were −$0.18. The operating margin was −22.5% (as of 3 November 2026). ### What is NeuroPace's market cap? NeuroPace, Inc.'s market capitalisation is $423 M at a stock price of $12.31. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is NeuroPace performing? NeuroPace, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 17 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will NeuroPace's stock price go up? This page does not forecast NeuroPace, Inc.'s stock price. What it shows instead: the stock price is $12.31. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is NeuroPace in its business cycle? NeuroPace, Inc.'s FY25 operating margin was −16.3%, against a 5-year range of −89.6% to −16.3%: the middle of its own range, neither a peak nor a low. The latest quarter was −22.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the NeuroPace story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is NeuroPace a stock worth studying right now? What the numbers show: NeuroPace, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.